daclizumab 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definitionDrug idCAS RN
human origin 4953 152923-56-3

Description:

MoleculeDescription

Synonyms:

  • zinbryta
  • daclizumab
  • zenapax
An anti-TAC (INTERLEUKIN-2 RECEPTOR ALPHA SUBUNIT) humanized monoclonal antibody (immunoglobulin G1 disulfide with human-mouse monoclonal clone 1H4 light chain, dimer) that is used in the treatment of ACUTE RELAPSING MULTIPLE SCLEROSIS.
  • Molecular weight:
  • Formula:
  • CLOGP:
  • LIPINSKI: None
  • HAC: None
  • HDO: None
  • TPSA:
  • ALOGS:
  • ROTB: None

Drug dosage:

DoseUnitRoute
5 mg P

ADMET properties:

None

Approvals:

DateAgencyCompanyOrphan
Feb. 26, 1999 EMA
Dec. 10, 1997 FDA HOFFMAN-LA ROCHE

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Transplant dysfunction 2399.88 47.75 405 4522 4341 56282799
Transplant rejection 1921.64 47.75 376 4551 9558 56277582
Ovarian cyst 1701.74 47.75 364 4563 14502 56272638
Acne 1590.24 47.75 367 4560 20769 56266371
Alopecia 789.86 47.75 418 4509 293040 55994100
Liver function test abnormal 403.59 47.75 151 4776 45520 56241620
Sleep disorder due to general medical condition, insomnia type 385.48 47.75 144 4783 43194 56243946
Multiple sclerosis relapse 268.31 47.75 112 4815 44791 56242349
Pneumonia 141.16 47.75 175 4752 406923 55880217
Condition aggravated 128.71 47.75 154 4773 344744 55942396
Loss of personal independence in daily activities 116.33 47.75 78 4849 81291 56205849
Rheumatoid arthritis 114.41 47.75 153 4774 382451 55904689
Incorrect route of product administration 93.93 47.75 43 4884 21286 56265854
Overdose 93.68 47.75 76 4851 105754 56181386
Kidney transplant rejection 85.09 47.75 26 4901 4187 56282953
Pain 75.34 47.75 173 4754 663011 55624129
Product use issue 59.29 47.75 77 4850 185964 56101176

FDA Adverse Event Reporting System (Male)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Multiple sclerosis relapse 149.70 37.74 36 530 12011 31684767

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Transplant dysfunction 2350.11 45.90 408 4658 6501 70916877
Ovarian cyst 1866.01 45.90 365 4701 11407 70911971
Transplant rejection 1753.79 45.90 373 4693 17798 70905580
Acne 1602.94 45.90 367 4699 24622 70898756
Alopecia 1020.29 45.90 416 4650 198074 70725304
Sleep disorder due to general medical condition, insomnia type 441.28 45.90 144 4922 35588 70887790
Liver function test abnormal 394.10 45.90 152 4914 60994 70862384
Multiple sclerosis relapse 305.90 45.90 115 4951 42902 70880476
Rheumatoid arthritis 172.57 45.90 152 4914 291653 70631725
Condition aggravated 132.17 45.90 157 4909 427478 70495900
Loss of personal independence in daily activities 127.81 45.90 78 4988 84832 70838546
Pneumonia 121.02 45.90 178 4888 596054 70327324
Pain 101.41 45.90 169 4897 628647 70294731
Incorrect route of product administration 93.37 45.90 43 5023 26449 70896929
Overdose 83.53 45.90 80 4986 169665 70753713
Product use issue 79.58 45.90 80 4986 179857 70743521
Drug ineffective 60.99 45.90 175 4891 939577 69983801
Encephalitis autoimmune 48.96 45.90 14 5052 2197 70921181

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

SourceCodeDescription
ATC L04AC01 ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS
IMMUNOSUPPRESSANTS
IMMUNOSUPPRESSANTS
Interleukin inhibitors
FDA MoA N0000010279 Interleukin 2 Receptor Antagonists
MeSH PA D007155 Immunologic Factors
MeSH PA D007166 Immunosuppressive Agents
FDA MoA N0000175621 Interleukin 2 Receptor-directed Antibody Interactions
FDA EPC N0000175622 Interleukin-2 Receptor Blocking Antibody

Drug Use | Suggest Off label Use Form| |View source of the data|

DiseaseRelationSNOMED_IDDOID
Renal transplant rejection indication 236570004
Relapsing remitting multiple sclerosis indication 426373005 DOID:2378




🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

None

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])
Mechanism
action
Bioact sourceMoA source
Interleukin-2 receptor Membrane receptor ANTIBODY BINDING Kd 8 IUPHAR DRUG LABEL

External reference:

IDSource
D03639 KEGG_DRUG
4021083 VUID
N0000148541 NUI
4021083 VANDF
CHEMBL1201605 ChEMBL_ID
6880 IUPHAR_LIGAND_ID
DB00111 DRUGBANK_ID
CUJ2MVI71Y UNII
1795335 RXNORM
11508 MMSL
241453 MMSL
4529 MMSL
d04262 MMSL
007284 NDDF
109133001 SNOMEDCT_US
386977009 SNOMEDCT_US
C0663182 UMLSCUI
D000077561 MESH_DESCRIPTOR_UI
7164 INN_ID

Pharmaceutical products:

None